E3 PreliminaryPreliminaryPEM not requiredReview-NarrativePeer-reviewedMachine draft
Astaxanthin: A Potential Mitochondrial-Targeted Antioxidant Treatment in Diseases and with Aging.
Sztretye, Mónika, Dienes, Beatrix, Gönczi, Mónika et al. · Oxidative medicine and cellular longevity · 2019 · DOI
Quick Summary
This review examines astaxanthin, a powerful natural antioxidant found in marine organisms, and how it might help protect cells from damage caused by oxidative stress—an imbalance that occurs in ME/CFS and many other diseases. The authors explain how astaxanthin may work by targeting and protecting mitochondria, the energy-producing structures in our cells. They suggest this compound could potentially help prevent or slow disease progression and aging-related health problems.
Why It Matters
Oxidative stress and mitochondrial dysfunction are widely recognized contributors to ME/CFS pathophysiology. This review identifies astaxanthin as a potentially promising mitochondrial-targeted antioxidant and may support the rationale for future clinical trials in ME/CFS populations.
Observed Findings
- Astaxanthin is identified as one of the most potent natural antioxidant compounds available
- Oxidative stress is documented as a hallmark feature of ME/CFS, alongside metabolic syndrome, neurodegenerative, cardiovascular, and inflammatory diseases
- Mitochondrial defects are recognized as major mediators of oxidative stress and aging-related diseases
- Mitochondrial-targeted antioxidants are proposed as a rational therapeutic strategy to prevent or slow disease progression
Inferred Conclusions
- Mitochondrial-targeted antioxidants may prevent or slow oxidative stress-driven pathophysiology in chronic diseases including ME/CFS
- Astaxanthin's robust natural antioxidant activity makes it a candidate for therapeutic investigation in oxidative stress-related conditions
- Antioxidant treatments warrant further study as potential disease-modifying interventions in aging and age-associated disease
Remaining Questions
- What is the efficacy and safety profile of astaxanthin in clinical ME/CFS populations specifically?
- What are the optimal dosing regimens and bioavailability characteristics of astaxanthin in human subjects?
- Does astaxanthin reduce disease biomarkers (oxidative stress markers, mitochondrial function) in ME/CFS patients, and does this translate to symptom improvement or functional gains?
What This Study Does Not Prove
This is a narrative review, not original research; it does not provide direct clinical evidence that astaxanthin improves ME/CFS outcomes. The review does not prove efficacy, safety, or optimal dosing in ME/CFS patients specifically, and correlation between antioxidant activity and clinical benefit has not been established. No human ME/CFS trial data is presented.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Metadata
- DOI
- 10.1155/2019/3849692
- PMID
- 31814873
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →